Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Digital Pathology Peer Review for GLP Toxicology Studies of Gene Therapies in the EU

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Digital Pathology Peer Review for GLP Toxicology Studies of Gene Therapies in the EU

Digital Pathology Peer Review for AAV Gene Therapy GxP Toxicology Studies

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    How does digital peer review align with EMA regulatory expectations for GxP toxicology studies?

    A: The EMA accepts data from validated digital pathology systems. Our workflow ensures that the whole-slide imaging (WSI) platform, image analysis algorithms, and data storage are fully validated to GxP standards, providing a complete, auditable record that meets regulatory requirements for data integrity and reproducibility.

    What is the validation process for the whole-slide imaging (WSI) systems?

    A: Our WSI systems undergo a rigorous validation protocol that includes Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ). We verify scanner precision, image fidelity against glass slides viewed with a conventional microscope, and inter-scanner consistency to ensure diagnostic concordance for GxP-level decision-making.

    How do you manage discordance between the primary pathologist and the peer reviewer in a digital environment?

    A: Discordant findings are managed through a defined resolution process. The digital platform facilitates a virtual consensus meeting where both board-certified pathologists can simultaneously review the same digital slide, annotate specific regions of interest, and reconcile interpretations. All communications and final decisions are documented in an audit trail.

    Can your digital platform integrate with our existing data management systems for streamlined reporting?

    A: Yes, our platform is designed for interoperability. We utilize standardized data formats and provide API access to facilitate secure integration with Sponsor LIMS or eTMF systems, ensuring pathology data and reports are transferred efficiently into your program’s central repository.

Executive Summary

Digital pathology peer review provides an objective, auditable, and efficient mechanism for confirming histology findings in GxP toxicology studies for adeno-associated virus (AAV) gene therapies. This process is vital for de-risking Investigational New Drug (IND) and Clinical Trial Authorisation (CTA) submissions, particularly for programs targeting the European Union. By leveraging a validated, remote workflow, we eliminate the logistical risks of shipping irreplaceable tissue samples and create a permanent digital archive for future analysis and regulatory inquiry.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

The Requirement for Objective Pathological Assessment in AAV Studies

The biological activity of AAV vectors requires rigorous and unbiased interpretation of all histology data from GxP toxicology studies. As the field pursues responsible development of AAV-based therapeutics [PMID: 40643951], the demand for verifiable pathological evaluation has intensified. An independent peer review of key findings by a second board-certified pathologist confirms the accuracy and interpretation of the primary read, strengthening the overall weight of evidence in the regulatory submission.

This level of verification helps secure the typical 18-24 month IND timeline by proactively addressing potential questions on pathological interpretation. Since 2019, our scientific teams have maintained a 100% IND success rate, a record of quality we bring to the Franklin Biolabs brand, which launched in 2024.

Implementing a GxP-Compliant Digital Peer Review Workflow

Our process digitizes the traditional peer review model to enhance data quality and security. This workflow provides rapid pathology insights accelerating preclinical readouts. The entire process is conducted within our >100,000 sq ft facility, which houses our integrated histology and digital imaging laboratories.

  • Whole-Slide Imaging (WSI): Glass slides from the toxicology study are scanned at high resolution using validated imaging systems to create digital files.

  • Secure Cloud Platform: Digital slides are uploaded to a secure, 21 CFR Part 11-compliant platform.

  • Primary Pathologist Review: The primary study pathologist conducts the initial evaluation and drafts the preliminary report directly within the digital environment.

  • Peer Reviewer Assignment: An independent, board-certified pathologist with relevant expertise is granted secure access to the digital case files for review.

  • Concordance & Reporting: The peer reviewer confirms or comments on the primary findings. Any discrepancies are resolved via the platform’s collaborative tools, and the final, peer-reviewed pathology report is issued.

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

Mitigating Vector-Related Biological Complexities

AAV gene therapy programs present unique challenges that demand a comprehensive preclinical data package. For instance, understanding the impact of preexisting neutralizing antibodies is a key consideration for interpreting in vivo study outcomes, as these can significantly alter vector transduction and subsequent tissue response [PMID: 26067568]. While histology does not directly measure NAb titers, it provides the definitive assessment of the resulting tissue-level effects. In collaboration with our strategic bioanalytical partners who perform NAb screening, our pathology team correlates those findings with the observed tissue response and non-target tissue biodistribution.

Animal Welfare and Program Integrity

Our commitment to responsible research is demonstrated through our strict adherence to animal welfare guidelines. All in vivo studies are conducted in facilities accredited by AAALAC International and registered with the USDA. We are dedicated to the principles of the 3Rs (Replacement, Reduction, and Refinement) to ensure the highest ethical standards in every program.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities